Your browser does not support JavaScript!

Samjin Pharma’s Second-Generation Co-Leadership and Tonix’s TNX-1500 Xenotransplantation Collaboration

General Report May 17, 2025
goover

TABLE OF CONTENTS

  1. Summary
  2. Samjin Pharmaceutical’s Transition to Second-Generation Co-Leadership
  3. Tonix Pharmaceuticals’ TNX-1500 Collaboration in Xenotransplantation
  4. Conclusion

1. Summary

  • As of May 17, 2025, the landscape of the pharmaceutical and biotech sectors is marked by significant developments from two prominent companies: Samjin Pharmaceutical and Tonix Pharmaceuticals. Samjin has undergone a transformative transition to a second-generation co-leadership model, appointing Cho Gyu-seok and Choi Ji-hyun as co-CEOs on March 12, 2025. This strategic move not only symbolizes a shift in corporate governance but also emphasizes the importance of legacy and familial stewardship. With their unique backgrounds—Cho being the son of the founder and Choi the daughter of the previous CEO—their leadership aims to harness combined experiences to navigate the highly competitive market environment. The company's robust sales growth, prominently driven by Gevorin, a key analgesic product, is indicative of its operational success, highlighted by impressive revenue exceeding 300 billion KRW last year, and a remarkable 54.4% increase in operating profitability. As the focus sharpens on governance-driven growth, expectations are high for sustained profitability alongside increased investments in innovative research and development.

  • Tonix Pharmaceuticals is making notable strides through its recent collaboration with Makana Therapeutics, formalized in a research agreement on April 9, 2025. This partnership is centered around the immunomodulatory candidate TNX-1500 and its application in xenotransplantation—a critical advancement in organ transplant medicine. TNX-1500, designed to mitigate immune rejection in transfusion scenarios, targets chronic challenges impeding the acceptance of transplanted organs such as kidneys, hearts, and islet cells. By leveraging genetically engineered pig organs, this collaboration not only aims to validate the preclinical data but also positions itself as a potential breakthrough in the xenotransplantation field. As demand for transplantable organs surges, this partnership emphasizes the growing necessity of innovative solutions capable of addressing the organ shortage crisis.

2. Samjin Pharmaceutical’s Transition to Second-Generation Co-Leadership

  • 2-1. Appointment of co-CEOs Cho Gyu-seok and Choi Ji-hyun

  • On March 12, 2025, Samjin Pharmaceutical announced the appointment of Cho Gyu-seok and Choi Ji-hyun as co-CEOs. This pivotal change marks a significant transition to a second-generation co-leadership model, showcasing a structured inheritance of stewardship within the founding families. Cho Gyu-seok is the son of the founder, Cho Ui-hwan, while Choi Ji-hyun is the daughter of former CEO Choi Seung-joo. Their dual leadership is aimed at combining their unique experiences and visions to further drive the company toward sustained growth, particularly in the context of today's competitive pharmaceutical landscape.

  • 2-2. Board composition of second-generation owners

  • The newly constituted board of directors for Samjin Pharmaceutical is entirely composed of second-generation owners. Alongside the co-CEOs, figures such as Vice Presidents Cho Gyu-hyung and Choi Ji-sun are key members. This strategic composition is expected to ensure continuity in corporate governance and a unified vision for the company's future direction. The emphasis on family lineage not only reflects a commitment to the company's heritage but also aims to strengthen stakeholder confidence in its governance structure.

  • 2-3. Sustained sales growth and core product portfolio (including Gevorin)

  • Samjin Pharmaceutical has showcased impressive sales growth, highlighted by a significant sales figure exceeding 300 billion KRW in the previous year. A particularly notable contributor to this growth is the traditional analgesic, Gevorin, which has consistently generated stable revenue, accounting for over 160 billion KRW. The strategic focus on optimizing the product range and enhancing operational efficiencies has resulted in a remarkable 54.4% increase in operating profit, indicating the company's robust performance, even amidst external challenges.

  • 2-4. Governance-driven growth outlook

  • Looking ahead, Samjin Pharmaceutical demonstrates a clear governance-driven growth outlook, supported by a structured strategy that prioritizes both core products and innovative research investments. The company aims to maintain sales growth through a projected 10% profitability structure for the current year, as noted by industry analysts. Investments in research and development have increased by 16% recently, reflecting a commitment to not only maintaining market leadership through established products but also advancing in new pharmaceutical innovations and technologies.

3. Tonix Pharmaceuticals’ TNX-1500 Collaboration in Xenotransplantation

  • 3-1. Agreement framework with Makana Bio

  • On April 9, 2025, Tonix Pharmaceuticals and Makana Therapeutics entered into a collaborative research agreement focusing on the use of TNX-1500, an investigational monoclonal antibody targeting CD40L, in xenotransplantation applications. This agreement aims to establish a comprehensive framework for integrating TNX-1500 into Makana’s preclinical studies of genetically engineered organs derived from pigs, specifically targeting kidney, heart, and islet cell transplantation. The collaboration is intended to facilitate necessary regulatory filings, including a potential investigational new drug application to the U.S. Food and Drug Administration (FDA) for compassionate use in clinical settings. Both companies express optimism that their partnership represents a significant step toward offering innovative solutions for patients suffering from organ failure.

  • 3-2. Mechanism of TNX-1500 as an immunomodulatory agent

  • TNX-1500 is characterized as an Fc-modified humanized monoclonal antibody that effectively binds to the CD40 ligand, a key player in the activation of immune responses. The mechanism of TNX-1500 involves the modulation of both antibody and cellular immune responses, making it a potent candidate for preventing rejection in xenotransplantation scenarios. By inhibiting CD40L engagement, TNX-1500 is designed to reduce the incidence of acute and chronic rejection of transplanted organs, which has historically been one of the critical barriers in xenotransplantation.

  • 3-3. Target organ programs: kidney, heart and islet cells

  • The collaboration between Tonix and Makana is set to encompass multiple organ transplantation programs, focusing on kidneys, hearts, and islet cells. The strategic selection of these organ types is rooted in the increasing demand for viable transplant options, especially as traditional allograft sources become increasingly scarce. By employing Makana’s genetically engineered pigs, which have been tailored to express reduced xenoantigen levels, the partnership aims to enhance the compatibility of these organs for transplant recipients. The preclinical studies undertaken through this collaboration will seek to validate this approach and prepare the groundwork for future clinical trials.

  • 3-4. Potential impact on xenotransplantation field

  • The implications of this collaboration are significant for the field of xenotransplantation. By integrating TNX-1500 as part of an immunomodulatory regimen, the partnership aims to address longstanding challenges related to organ rejection, a central concern impeding the clinical application of xenotransplantation therapies. Furthermore, the collaboration could potentially accelerate the timeline for clinical application, allowing advancements in organ transplantation to progress more swiftly. As the global demand for transplantable organs continues to rise, innovative solutions such as this partnership are vital for overcoming existing limitations and expanding patient access to life-saving procedures.

Conclusion

  • The strategic appointments of Cho Gyu-seok and Choi Ji-hyun as co-CEOs of Samjin Pharmaceutical constitute a pivotal point in the company's governance evolution, merging familial legacy with ambitious growth prospects. By aligning their leadership with the company's established strengths—including the consistent sales performance of Gevorin—the organization is poised to enhance its operational efficiency and continue its trajectory of profitability. Furthermore, Samjin's commitment to invest significantly in research and development reflects an understanding of the need for innovation in driving future success, ensuring the company maintains its competitive edge in an ever-evolving market landscape.

  • Concurrently, Tonix Pharmaceuticals' partnership with Makana Bio introduces a pioneering approach to xenotransplantation through the application of TNX-1500. By targeting the critical issue of organ rejection, this collaboration represents a significant milestone in the race to expand viable transplant options amidst a global shortage of organ donors. The dual focus on kidneys, hearts, and islet cells underlines the partnership's dedication to addressing urgent healthcare needs and maximizing the potential for successful translational outcomes. Looking ahead, both companies will require rigorous monitoring of their strategic initiatives—Samjin's co-leadership execution and Tonix’s ongoing clinical advancements with TNX-1500—as these elements are likely to substantially influence the future of healthcare solutions in their respective fields. The insights gained from these developments not only illuminate the dynamics of corporate governance in the pharmaceutical sector but also the ongoing innovations aiming to transform clinical practices.

Glossary

  • Samjin Pharma: A notable pharmaceutical company that has transitioned to a second-generation co-leadership model with new co-CEOs appointed in March 2025, aiming for sustained sales growth and innovation-driven strategies.
  • Co-CEO: A leadership structure where two executives share the chief executive officer position, allowing for diverse experiences and perspectives, as seen with Cho Gyu-seok and Choi Ji-hyun at Samjin Pharma.
  • Second-Generation: Refers to the leadership transition in family-owned businesses, where the next generation assumes control, emphasizing continuity in governance and the legacy of the founders.
  • Corporate Governance: The system by which companies are directed and controlled, focusing on the roles of board members, executive leadership, and stakeholder interests, especially relevant in the context of Samjin Pharma’s changes.
  • Sales Growth: An increase in a company's sales over time, which is demonstrated by Samjin Pharma's revenue exceeding 300 billion KRW and a notable increase in profitability as of May 2025.
  • Gevorin: An analgesic product from Samjin Pharma that has played a critical role in the company's sales stability, contributing over 160 billion KRW to revenue.
  • Tonix Pharmaceuticals: A biotech company currently collaborating with Makana Bio on the development of its immunomodulatory candidate, TNX-1500, aimed at enhancing xenotransplantation.
  • TNX-1500: An investigational monoclonal antibody targeting CD40L, designed to reduce organ rejection in xenotransplantation, reflecting advances in immunology and transplant medicine.
  • Xenotransplantation: A medical procedure involving the transplantation of organs or tissues from one species to another, notably utilizing genetically engineered pig organs in ongoing studies to mitigate organ shortages.
  • Immunomodulation: The process of altering the immune response to improve outcomes in therapies, such as those involving TNX-1500, which aims to prevent organ rejection during transplantation.
  • Makana Bio: A biotechnology company that partners with Tonix Pharmaceuticals for research on TNX-1500, focusing on applications in preclinical studies of genetically engineered pig organs.
  • Investigational New Drug Application (IND): An application submitted to the U.S. Food and Drug Administration (FDA) to initiate clinical trials of new therapeutic products, relevant to the collaboration between Tonix Pharmaceuticals and Makana Bio.
  • Fc-modified Humanized Monoclonal Antibody: A type of engineered antibody designed to enhance the efficacy of immune modulation by modifying its structure, as seen with TNX-1500 to better bind to CD40L.
  • Chronic Rejection: A long-term rejection response to transplanted organs that requires innovative therapeutic strategies, like those proposed with TNX-1500 in xenotransplantation.

Source Documents